“I want to give you a million dollars.”

The delivery was direct. Almost disarmingly so. No buildup, no formal pitch—just a few words delivered the way J. Michael Dean has approached much of his career: clearly, decisively, and without ceremony. On the other end of the line, Jamie P. Dwyer, MD, understood immediately what the moment represented.

“My first thought was immense gratitude,” Dwyer shared, “And also happiness that he thought I was doing a good enough job to shepherd his baby, the Utah Data Coordinating Center (DCC),  through the next phase.”

Dean is now retired from day-to-day operations. But the Utah Data Coordinating Center he founded at the University of Utah continues to operate at a national scale, supporting complex multi-site clinical trials and coordinating research efforts across the country.

Even in retirement, he remains invested in what comes next, less interested in looking back than in ensuring the system and infrastructure he built continues to evolve.

Stepping Ahead of the Curve Early On

When Dean mentioned that the Apple II he bought in 1977 had a serial number under 10,000, he didn’t linger on the detail. But in retrospect, it says something essential about the kind of physician and builder he would become.

At the time, personal computing was still experimental, a space occupied primarily by engineers, hobbyists, and the unusually curious. Dean, conversely, was a pediatric resident at Children’s Hospital of Los Angeles.

“I became completely addicted to computer programming,” he shared, noting that the moment marked the beginning of a habit that would define much of his career.

Dean entered Northwestern’s accelerated six-year medical program directly out of high school, trained in pediatric critical care at The Johns Hopkins Hospital, and gravitated toward high-acuity environments where decisions carried immediate consequences. But alongside that clinical intensity, he was already moving in a different direction, teaching himself programming, securing an early grant from Apple, and building simulation tools long before such work was common in medicine.

Throughout his career, Dean gravitated toward problems others hadn’t yet organized around, teaching himself what the moment required, then building systems others would eventually depend on.

Dean didn’t set out to build a national research enterprise. He wrote his own code, built his own databases, and analyzed his own data because, as he put it, “I needed to understand it.”

The approach was more about fluency than control. If something was central to the work, Dean believed he needed to know it well enough to execute it himself. Over time, his habit of getting close to the work and learning systems from the inside out became a standard for his work.

“We may not win every project,” he admitted. “But we go into those conversations knowing we understand the problem at a very high level. That matters.”

As the organization expanded, that expectation shaped how teams approached problems. The expectation wasn’t just to participate in the work, but to understand it deeply. This would come to define the culture of the organization he would eventually build.

Where the Systems Came Together

When Dean arrived in Utah in the late 1980s, an opportunity in emergency medical services introduced him to a problem: critical data existed everywhere in ambulance records, crash data, and hospital systems, but none of it was connected.

Using probabilistic database linkage, Dean and his collaborators connected datasets that were never designed to communicate with one another. Questions that once required new data collection could suddenly be answered using information that already existed.

Dean’s experience with probabilistic database linkage eventually formed the beginning of the infrastructure that led to the formation of the Data Coordinating Center.

The DCC coordinates the infrastructure behind large, multi-site clinical research: trial design, regulatory management, data systems, analytics, and operational oversight.

“If you have a disease that’s not very common, you build a network,” Dean explained. “the Data Coordinating Center coordinates the whole thing.”

What began organically—one opportunity leading to the next—has grown into something far more substantial. Today, the DCC supports roughly 100 active studies with a workforce of 172 people;  spanning biostatistics, clinical operations, regulatory expertise, and trial design.

“The breadth of our experience is a huge advantage,” Dean discussed. “It gives the University the opportunity to get into any kind of research it goes after.”

Changing Leadership and Consistent Values

The DCC’s operating model, with an unusual scale and breadth, is what Dwyer inherited, and what he is now responsible for advancing.

As a physician-scientist and entrepreneur, Dwyer leads the University’s innovation and commercialization strategy while directing the DCC, successfully connecting research to application, and discovery to deployment.

The alignment between founder and successor was immediate.

“We think in very similar ways,” Dwyer shared. “[Dean] is a force of nature. The scale of what he built, and the way he built it, creates its own gravity.”

What Dean built, Dwyer emphasizes, is not easily recreated because it would be “much more transactional [today]. Price would drive decisions, not quality.” That continuity has created unusually deep institutional knowledge.

Dean’s $1 million gift is designed to accelerate growth. He described it as a “first grant,” a way to create momentum. It signals belief in the organization and its leadership.

“This is a rare kind of investment,” he shared. “It’s about trust—trust in [Dwyer] and in the direction of the work.”

The investment will strengthen the DCC’s ability to support industry partnerships, expand its technical infrastructure, and position itself for larger, more flexible funding streams.

A central focus is technology, particularly the integration of artificial intelligence into clinical research operations. Many of the bottlenecks in clinical trials are procedural rather than scientific. Protocol development, regulatory documentation, and site initiation can take months, even when the underlying science is relatively straightforward.

“The timelines don’t match the urgency of the questions we’re trying to answer,” Dwyer stated. “There’s a lot of friction in the system.”

Reducing that friction has become a strategic priority, with the goal of improving consistency, shortening administrative delays, and allowing the DCC to move at a pace that aligns with both academic and industry expectations.

“I think the next decade is going to look very different,” Dwyer said. “We’re going to see new types of studies supporting FDA approvals, new ways of thinking about evidence.”